Andrew W Silagy1, Alejandro Sanchez2, Brandon J Manley3, Karim Bensalah4, Axel Bex5, Jose A Karam6, Börje Ljungberg7, Brian Shuch8, A Ari Hakimi9. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Victoria, Australia. 2. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Moffitt Cancer Center Genitourinary Oncology and Integrated Mathematical Oncology, Tampa, FL, USA. 4. Department of Urology, University of Rennes, Rennes, France. 5. Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK; The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden. 8. UCLA School of Medicine, Los Angeles, CA, USA. 9. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.
Abstract
CONTEXT: Small renal masses (SRMs; tumors <4 cm) encompass a diagnostic and therapeutic challenge. Genomic profiling has the potential to improve risk stratification and personalize treatment selection. OBJECTIVE: Herein, we review the evidence regarding the utility, challenges, and potential implications of genomic profiling in the management of SRMs. EVIDENCE ACQUISITION: Pertinent publications available on PubMed database pertaining to kidney cancer, tumor size, genomics, and clinical management were reviewed. EVIDENCE SYNTHESIS: Compared with larger tumors, SRMs range from benign to lethal, necessitating strategies for improved treatment selection. Recent advances in the molecular characterization of renal cell carcinoma have improved our understanding of the disease; however, utility of these tools for the management of SRMs is less clear. While intratumoral heterogeneity (ITH) reduces the accuracy and reliability of sequencing, relative genomic uniformity of SRMs somewhat lessens the impact of ITH. Therefore, renal mass biopsy of SRMs represents an appealing opportunity to evaluate how incorporation of molecular profiles may improve management strategies. CONCLUSIONS: Ongoing research into the genomic landscape of SRMs has advanced our understanding of the spectrum of disease aggressiveness and may hold promise in matching disease biology to treatment intensity. PATIENT SUMMARY: Small renal masses are a clinical challenge, as they range from benign to lethal. Genomic profiling may eventually improve treatment selection, but more research is needed.
CONTEXT: Small renal masses (SRMs; tumors <4 cm) encompass a diagnostic and therapeutic challenge. Genomic profiling has the potential to improve risk stratification and personalize treatment selection. OBJECTIVE: Herein, we review the evidence regarding the utility, challenges, and potential implications of genomic profiling in the management of SRMs. EVIDENCE ACQUISITION: Pertinent publications available on PubMed database pertaining to kidney cancer, tumor size, genomics, and clinical management were reviewed. EVIDENCE SYNTHESIS: Compared with larger tumors, SRMs range from benign to lethal, necessitating strategies for improved treatment selection. Recent advances in the molecular characterization of renal cell carcinoma have improved our understanding of the disease; however, utility of these tools for the management of SRMs is less clear. While intratumoral heterogeneity (ITH) reduces the accuracy and reliability of sequencing, relative genomic uniformity of SRMs somewhat lessens the impact of ITH. Therefore, renal mass biopsy of SRMs represents an appealing opportunity to evaluate how incorporation of molecular profiles may improve management strategies. CONCLUSIONS: Ongoing research into the genomic landscape of SRMs has advanced our understanding of the spectrum of disease aggressiveness and may hold promise in matching disease biology to treatment intensity. PATIENT SUMMARY: Small renal masses are a clinical challenge, as they range from benign to lethal. Genomic profiling may eventually improve treatment selection, but more research is needed.
Authors: Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell Journal: Eur Urol Date: 2014-02-25 Impact factor: 20.096
Authors: Andrea Sboner; Xinmeng Jasmine Mu; Dov Greenbaum; Raymond K Auerbach; Mark B Gerstein Journal: Genome Biol Date: 2011-08-25 Impact factor: 13.583
Authors: Joel Prince; Eric Bultman; Louis Hinshaw; Anna Drewry; Michael Blute; Sara Best; Fred T Lee; Timothy Ziemlewicz; Meghan Lubner; Fangfang Shi; Stephen Y Nakada; E Jason Abel Journal: J Urol Date: 2014-12-11 Impact factor: 7.450
Authors: R Houston Thompson; Jordan M Kurta; Matthew Kaag; Satish K Tickoo; Shilajit Kundu; Darren Katz; Lucas Nogueira; Victor E Reuter; Paul Russo Journal: J Urol Date: 2009-03-14 Impact factor: 7.450
Authors: Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: J Ricardo Rivero; Jose De La Cerda; Hanzhang Wang; Michael A Liss; Ann M Farrell; Ronald Rodriguez; Rajeev Suri; Dharam Kaushik Journal: J Vasc Interv Radiol Date: 2018-01 Impact factor: 3.464
Authors: Alexander Sankin; Abraham A Hakimi; Nina Mikkilineni; Irina Ostrovnaya; Mikhail T Silk; Yupu Liang; Roy Mano; Michael Chevinsky; Robert J Motzer; Stephen B Solomon; Emily H Cheng; Jeremy C Durack; Jonathan A Coleman; Paul Russo; James J Hsieh Journal: Cancer Med Date: 2014-08-14 Impact factor: 4.452
Authors: Roy Mano; Cihan Duzgol; Maz Ganat; Debra A Goldman; Kyle A Blum; Andrew W Silagy; Aleksandra Walasek; Alejandro Sanchez; Renzo G DiNatale; Julian Marcon; Mahyar Kashan; Maria F Becerra; Nicole E Benfante; Jonathan A Coleman; Michael W Kattan; Paul Russo; Oguz Akin; Irina Ostrovnaya; A Ari Hakimi Journal: Urol Oncol Date: 2021-09-25 Impact factor: 3.498